SCHEMBL30774426

SCHEMBL30774426

N#Cc1ccc(-c2cncc3c2CCN3C(=O)c2ccc(F)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 9/20 0.48
▸ USP30 Q70CQ3 2/20 0.46
▸ UCHL1 P09936 1/20 0.46
▸ CYP11B1 P15538 6/20 0.43
▸ KDM1A O60341 1/20 0.42
▸ SLC22A12 Q96S37 1/20 0.42
▸ PRKAA2 P54646 3/20 0.41
▸ PRKAB2 O43741 2/20 0.41
▸ PRKAG1 P54619 2/20 0.41
▸ PRKAA1 Q13131 2/20 0.41
▸ PRKAG3 Q9UGI9 2/20 0.41
▸ PRKAG2 Q9UGJ0 2/20 0.41
▸ PRKAB1 Q9Y478 2/20 0.41
▸ PDCD1 Q15116 2/20 0.41
▸ CD274 Q9NZQ7 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30774625 0.94 USP30 (0.49) CYP11B2USP30UCHL1CYP11B1SLC22A12
SCHEMBL33532547 0.90 SLC22A12 (0.50) CYP11B2USP30UCHL1CYP11B1SLC22A12
SCHEMBL30774411 0.90 KDM1A (0.47) CYP11B2USP30UCHL1CYP11B1KDM1A
SCHEMBL30774532 0.89 USP30 (0.46) CYP11B2USP30UCHL1CYP11B1KDM1A
SCHEMBL30774475 0.89 USP30 (0.46) CYP11B2USP30UCHL1CYP11B1KDM1A
SCHEMBL30774581 0.88 GAA (0.48) CYP11B2USP30UCHL1PDCD1CD274
SCHEMBL30774401 0.87 CYP11B2 (0.44) CYP11B2USP30UCHL1CYP11B1SLC22A12
SCHEMBL30774430 0.87 PDCD1 (0.44) CYP11B2USP30UCHL1CYP11B1PDCD1
SCHEMBL31635535 0.87 PDCD1 (0.44) CYP11B2USP30UCHL1CYP11B1PDCD1
SCHEMBL30774399 0.87 CYP11B2 (0.51) CYP11B2USP30UCHL1CYP11B1PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US claimed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP claimed
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof GUANGZHOU VINNOCENT PHARMACEUTICAL LTD (CN) 2026-04-02 — — US disclosed
EP-4574830-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Guangzhou Vinnocent Pharmaceutical Limited (CN) 2025-06-25 — — EP disclosed
WO-2024061371-A1 ANNELATED PYRIDINE STEROID SYNTHETASE INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 广州威诺森医药科技有限公司 2024-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092074-A1 Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof STS, NR5A1, CYP21A2 CYP11B2 38/4885USP30 728/4885UCHL1 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback